High Incidence of C797S Mutation in Patients With Long Treatment History of EGFR Tyrosine Kinase Inhibitors Including Osimertinib

INTRODUCTION: Although treatment with osimertinib confers survival benefits in patients with lung cancer with the EGFR T790M mutation, the mechanism of acquired resistance to osimertinib remains poorly understood. We conducted a prospective observational study to identify the mechanism on the basis...

Descripción completa

Detalles Bibliográficos
Autores principales: Osoegawa, Atsushi, Yamaguchi, Masafumi, Nakamura, Tomomi, Morinaga, Ryotaro, Tanaka, Kentaro, Kashiwabara, Kosuke, Miura, Takashi, Suetsugu, Takayuki, Harada, Taishi, Asoh, Tatsuma, Taguchi, Kenichi, Nabeshima, Kazuki, Kishimoto, Junji, Sakai, Kazuko, Nishio, Kazuto, Sugio, Kenji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474195/
https://www.ncbi.nlm.nih.gov/pubmed/34590037
http://dx.doi.org/10.1016/j.jtocrr.2021.100191

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474195/
https://www.ncbi.nlm.nih.gov/pubmed/34590037
http://dx.doi.org/10.1016/j.jtocrr.2021.100191

Ejemplares similares